• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    7/10/23 1:50:32 PM ET
    $STRC
    $TCBP
    $TEAF
    $TGL
    Wholesale Distributors
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $STRC alert in real time by email

     

    On Monday, 65 companies hit new 52-week lows.

    Things to Consider About Today's 52-Week Lows:

    • The largest company by market cap to set a new 52-week low was Pfizer (NYSE:PFE).
    • The smallest company in terms of market cap to set a new 52-week low was Biodexa Pharmaceuticals (NASDAQ:BDRX).
    • Tivic Health Systems (NASDAQ:TIVC) shares traded down 40.69% to reach its 52-week low, making it the biggest loser.
    • Chijet Motor Co (NASDAQ:CJET) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low.

    Stocks dropping to new 52-week lows on Monday:

    • Bristol-Myers Squibb (NYSE:BMY) shares fell to $62.30 on Monday, setting a new 52-week low with a shift of down 0.54%.
    • Humana (NYSE:HUM) shares reached a new 52-week low of $427.21 on Monday morning, moving up 0.06%.
    • Amcor (NYSE:AMCR) stock hit a new 52-week low of $9.48. The stock was down 3.77% on the session.
    • FMC (NYSE:FMC) stock hit $88.80 on Monday morning, setting a new 52-week low for a change of down 14.62%.
    • KT (NYSE:KT) shares fell to $11.10 on Monday, setting a new 52-week low with a shift of up 0.04%.
    • UGI (NYSE:UGI) shares were down 0.81% for the day, having made a 52-week low of $25.69.
    • Clearway Energy (NYSE:CWEN) shares moved down 0.29% on Monday to hit a new 52-week low of $27.38, drifting down 0.29%.
    • California Water Servs Gr (NYSE:CWT) shares set a new yearly low of $49.27 this morning. The stock was down 0.37% on the session.
    • SunPower (NASDAQ:SPWR) stock hit a new 52-week low of $8.99. The stock was up 1.49% on the session.
    • Northwest Natural Hldg (NYSE:NWN) shares reached a new 52-week low of $41.64 on Monday morning, moving up 0.12%.
    • Duckhorn Portfolio (NYSE:NAPA) stock broke to a new 52-week low of $12.54 on Monday. Shares of the company traded down 1.41%.
    • Kenon Hldgs (NYSE:KEN) stock achieved a new 52-week low on Monday morning, hitting $22.85 and moving down 2.52%.
    • Enanta Pharma (NASDAQ:ENTA) shares were up 1.69% for the day, having made a 52-week low of $19.29.
    • Chijet Motor Co (NASDAQ:CJET) stock achieved a new 52-week low on Monday morning, hitting $2.31 and moving 0.0% (flat).
    • First Foundation (NASDAQ:FFWM) shares made a new 52-week low of $3.75 on Monday. The stock was down 0.52% for the day.
    • Douglas Elliman (NYSE:DOUG) shares were up 5.6% for the day, having made a 52-week low of $2.07.
    • Tortoise Essential Assets (NYSE:TEAF) shares moved down 0.32% on Monday to hit a new 52-week low of $12.20, drifting down 0.32%.
    • Delaware Inv Natl Muni (AMEX:VFL) shares fell to $9.85 on Monday, setting a new 52-week low with a shift of down 0.2%.
    • OptiNose (NASDAQ:OPTN) stock hit $1.05 on Monday morning, setting a new 52-week low for a change of down 4.02%.
    • Cherry Hill Mortgage (NYSE:CHMI) shares fell to $4.33 on Monday, setting a new 52-week low with a shift of down 0.23%.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) shares moved up 1.24% on Monday to hit a new 52-week low of $2.38, drifting up 1.24%.
    • Jerash Holdings (US) (NASDAQ:JRSH) stock dropped to a yearly low on Monday of $3.64. Shares traded down 1.35%.
    • 22nd Century Group (NASDAQ:XXII) shares hit a yearly low of $2.42. The stock was down 7.47% on the session.
    • Interactive Strength (NASDAQ:TRNR) shares fell to $2.49 on Monday, setting a new 52-week low with a shift of up 3.44%.
    • Sarcos Technology (NASDAQ:STRC) stock hit $1.46 on Monday morning, setting a new 52-week low for a change of down 6.23%.
    • Yunji (NASDAQ:YJ) stock hit a new 52-week low of $1.27. The stock was down 7.64% on the session.
    • Psychemedics (NASDAQ:PMD) shares set a new 52-week low of $4.19. The stock traded up 0.46%.
    • Tattooed Chef (NASDAQ:TTCF) shares reached a new 52-week low of $0.21 on Monday morning, moving down 11.54%.
    • Powerbridge Technologies (NASDAQ:PBTS) stock hit $0.61 on Monday morning, setting a new 52-week low for a change of down 2.25%.
    • Cineverse (NASDAQ:CNVS) stock hit a yearly low of $1.53. The stock was down 3.4% for the day.
    • Treasure Global (NASDAQ:TGL) shares fell to $0.90 on Monday, setting a new 52-week low with a shift of down 3.29%.
    • Avalon Globocare (NASDAQ:ALBT) stock set a new 52-week low of $1.19 on Monday, moving up 6.19%.
    • ABVC BioPharma (NASDAQ:ABVC) shares set a new 52-week low of $0.44. The stock traded down 2.06%.
    • FOXO Technologies (AMEX:FOXO) shares moved down 7.27% on Monday to hit a new 52-week low of $0.18, drifting down 7.27%.
    • Greenwave Tech Solns (NASDAQ:GWAV) stock dropped to a yearly low on Monday of $0.70. Shares traded down 3.1%.
    • T Stamp (NASDAQ:IDAI) shares were down 5.37% for the day, having made a 52-week low of $0.96.
    • iSun (NASDAQ:ISUN) shares set a new 52-week low of $0.37. The stock traded down 1.19%.
    • Ault Alliance (AMEX:AULT) shares fell to $4.86 on Monday, setting a new 52-week low with a shift of down 1.78%.
    • Enservco (AMEX:ENSV) stock broke to a new 52-week low of $0.29 on Monday. Shares of the company traded up 2.07%.
    • OceanPal (NASDAQ:OP) stock broke to a new 52-week low of $1.26 on Monday. Shares of the company traded down 7.56%.
    • SuperCom (NASDAQ:SPCB) shares made a new 52-week low of $0.92 on Monday. The stock was up 0.36% for the day.
    • Ra Medical Systems (AMEX:RMED) shares set a new 52-week low of $0.70. The stock traded down 5.47%.
    • Gaucho Group Holdings (NASDAQ:VINO) shares moved up 1.99% on Monday to hit a new 52-week low of $0.50, drifting up 1.99%.
    • Blue Star Foods (NASDAQ:BSFC) stock hit a new 52-week low of $1.05. The stock was down 5.65% on the session.
    • Ucommune International (NASDAQ:UK) shares made a new 52-week low of $0.50 on Monday. The stock was up 1.63% for the day.
    • G Medical Innovations (NASDAQ:GMVD) shares made a new 52-week low of $0.32 on Monday. The stock was up 1.73% for the day.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares set a new 52-week low of $0.43. The stock traded down 1.97%.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares were down 2.76% for the day, having made a 52-week low of $3.76.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $STRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STRC
    $TCBP
    $TEAF
    $TGL

    CompanyDatePrice TargetRatingAnalyst
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Amcor plc
    $AMCR
    1/28/2026$46.00Overweight → Equal-Weight
    Morgan Stanley
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Humana Inc.
    $HUM
    1/7/2026$290.00Overweight → Equal Weight
    Wells Fargo
    Amcor plc
    $AMCR
    1/7/2026$10.00Neutral → Outperform
    Robert W. Baird
    Bristol-Myers Squibb Company
    $BMY
    1/7/2026$65.00Neutral → Buy
    UBS
    Clearway Energy Inc.
    $CWEN
    12/17/2025$38.00Neutral → Sector Outperform
    CIBC
    Bristol-Myers Squibb Company
    $BMY
    12/15/2025$61.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $STRC
    $TCBP
    $TEAF
    $TGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Digital & Tech Off. Meyers Gregory Scott converted options into 2,543 shares and covered exercise/tax liability with 833 shares, increasing direct ownership by 9% to 21,428 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/3/26 4:40:10 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, RayzeBio Org. Hickey Benjamin converted options into 10,079 shares and covered exercise/tax liability with 3,810 shares, increasing direct ownership by 71% to 15,058 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/3/26 4:39:19 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Yale Phyllis R

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/3/26 4:36:45 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STRC
    $TCBP
    $TEAF
    $TGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dietze Jane A bought $99,485 worth of Series A Perpetual Stretch Preferred Stock (1,000 units at $99.48), increasing direct ownership by 38% to 3,600 units (SEC Form 4)

    4 - Strategy Inc (0001050446) (Issuer)

    1/21/26 4:45:05 PM ET
    $STRC
    Wholesale Distributors
    Industrials

    Director Rickertsen Carl J bought $779,395 worth of shares (5,000 units at $155.88) (SEC Form 4)

    4 - Strategy Inc (0001050446) (Issuer)

    1/12/26 4:10:03 PM ET
    $STRC
    Wholesale Distributors
    Industrials

    President & CEO Le Phong bought $1,200 worth of Series A Perpetual Stretch Preferred Stock (12 units at $99.99) (SEC Form 4)

    4 - Strategy Inc (0001050446) (Issuer)

    1/9/26 4:38:08 PM ET
    $STRC
    Wholesale Distributors
    Industrials

    $STRC
    $TCBP
    $TEAF
    $TGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Humana downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Humana from Equal-Weight to Underweight and set a new price target of $174.00

    2/2/26 6:49:06 AM ET
    $HUM
    Medical Specialities
    Health Care

    Amcor downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Amcor from Overweight to Equal-Weight and set a new price target of $46.00

    1/28/26 2:25:29 PM ET
    $AMCR
    Miscellaneous manufacturing industries
    Consumer Discretionary

    UBS resumed coverage on Pfizer with a new price target

    UBS resumed coverage of Pfizer with a rating of Neutral and set a new price target of $25.00

    1/7/26 9:13:33 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STRC
    $TCBP
    $TEAF
    $TGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

    Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026 On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026 for EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate On Track to File an IND in 2H 2026 for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate Strong Financial Position of $241.9 Million Supported by Continuing Retained Roya

    2/9/26 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cineverse Launches Matchpoint® Creative Labs, Leveraging Generative AI to Enable Creative Services for FAST and Ad-Supported Streaming Services

    New In-House Agency Specializes in Developing Motion-First Creative for Advertising,On-Air Promotions, and Channel Branding Company Aims for Unit to Generate More than $4.5 Million in Revenue Within First Year LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), an innovative and independent entertainment technology company and studio, today announced the launch of Matchpoint® Creative Labs (MCL). Cineverse's new in-house agency, MCL was established to support the growing creative demands of connected TV (CTV), free ad-supported streaming television (FAST) channels, and streaming services.

    2/9/26 9:00:00 AM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

    Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, HYMPAVZI would become the first non-factor prophylactic treatment available for children aged 6 to 11 years with hemophilia B Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patient

    2/6/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STRC
    $TCBP
    $TEAF
    $TGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STRC
    $TCBP
    $TEAF
    $TGL
    SEC Filings

    View All

    SEC Form DEFA14A filed by Tivic Health Systems Inc.

    DEFA14A - Tivic Health Systems, Inc. (0001787740) (Filer)

    2/9/26 4:46:06 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    2/9/26 4:45:28 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    2/9/26 4:15:26 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STRC
    $TCBP
    $TEAF
    $TGL
    Leadership Updates

    Live Leadership Updates

    View All

    UGI Corporation Appoints Sidd Manjeshwar as Chief Strategy Officer

    UGI Corporation (NYSE:UGI) today announced that Sidd Manjeshwar has joined as Chief Strategy Officer and serves as part of the company's executive leadership team. In this newly created role, Manjeshwar will be responsible for formulating and driving UGI's enterprise vision and strategy, and leading strategic initiatives including assessing growth opportunities. Robert Flexon, President and CEO of UGI Corporation, said, "Over the past year, we have been focused on operational excellence and business turnaround, to drive greater intrinsic value and solidify our foundation. As we advance this crucial work, Sidd's extensive experience in corporate strategy, M&A, and value creation will help

    2/4/26 5:15:00 PM ET
    $UGI
    Natural Gas Distribution
    Utilities

    FMC Corporation sets 2026 priorities and announces exploration of strategic options including but not limited to the sale of the company

    Company reports 2025 fourth quarter and full year results, provides 2026 outlook  The organization continues to focus on its 2026 operational priorities, including strengthening the balance sheet, improving the competitiveness of its core portfolio, managing its post-patent Rynaxypyr® active strategy and supporting growth of new active ingredientsThe FMC Board of Directors has authorized the exploration of strategic options, including but not limited to, the sale of the company to unlock shareholder value and ensure its growth and core portfolios are best positioned for long-term success PHILADELPHIA, Feb. 4, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today announced its 2026 prioritie

    2/4/26 5:00:00 PM ET
    $FMC
    Major Chemicals
    Industrials

    Cineverse and GameStop Invite Fans to 'Return to Silent Hill' with Innovative Partnership featuring Mysterious Messages, Exclusive Rewards, In-Store Media & More

    Return to Silent Hill Hits Theaters Nationwide on January 23 – Buy Tickets Now LOS ANGELES and GRAPEVINE, Texas, Jan. 14, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), a next generation entertainment studio, and GameStop Corp. (NYSE:GME), are pulling out all the stops in anticipation of the January 23 wide theatrical release of Return to Silent Hill (returntosilenthillmovie.com).  The two companies are collaborating on an immersive marketing campaign for the new film, based on the visionary video game, SILENT HILL 2. Since January 7, fans who visit a participating GameStop ca

    1/14/26 3:02:00 PM ET
    $CNVS
    $GME
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Electronics Distribution

    $STRC
    $TCBP
    $TEAF
    $TGL
    Financials

    Live finance-specific insights

    View All

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

    Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026 On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026 for EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate On Track to File an IND in 2H 2026 for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate Strong Financial Position of $241.9 Million Supported by Continuing Retained Roya

    2/9/26 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    California Water Service Group Schedules 2025 Full-Year and Fourth-Quarter Earnings Results Announcement and Conference Call

    SAN JOSE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- California Water Service Group (NYSE:CWT) today announced that its 2025 full-year and fourth-quarter earnings results will be released after market-close on Wednesday, February 25, 2026, and its earnings conference call will be held at 11:00 a.m. ET on Thursday, February 26, 2026. All stockholders and interested investors are invited to attend the conference call. To attend, please dial 1-800-715-9871 or 1-646-307-1963 and key in ID# 2201083, or you may access the live audio webcast at https://edge.media-server.com/mmc/p/gc36wzai Please join at least 15 minutes in advance to ensure a timely connection to the call. A replay of the call w

    2/5/26 4:05:00 PM ET
    $CWT
    Water Supply
    Utilities

    Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

    Bristol Myers Squibb (NYSE:BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed fourth quarter and full-year 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb:

    2/5/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STRC
    $TCBP
    $TEAF
    $TGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/12/24 5:15:40 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Enservco Corporation

    SC 13D/A - Enservco Corp (0000319458) (Subject)

    12/10/24 4:00:16 PM ET
    $ENSV
    Oilfield Services/Equipment
    Energy

    Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

    SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/6/24 9:18:20 PM ET
    $PMD
    Medical Specialities
    Health Care